Using transcriptomic data from the BELOB phase II trial, which compared lomustine versus lomustine plus bevacizumab in recurrent glioblastoma, we confirmed that CSF3 expression was overexpressed in mesenchymal tumors and correlated with VEGFA expression (see eFigure 5 in the Supplement). Here, CSF3 is linked to mesenchymal cell neoplasm.